Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-01

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study

NCT03776682

Myocardial Inflammation Rheumatoid Arthritis Coronary Artery Disease +1 more

COMPLETED

Assessment of 14-3-3 η (Eta) Protein Antibodies in the Serum of Rheumatoid Arthritis Patients and Its Relation to Atherosclerosis.

NCT04937140

Rheumatoid Arthritis

UNKNOWN

Rheumatoid Arthritis Disease Activity and Sub Clinical Atherosclerosis

NCT03821090

Rheumatoid Arthritis

COMPLETED

Comprehensive Assessment of Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis

NCT03813017

Cardiovascular Diseases Rheumatoid Arthritis Atherosclerosis, Coronary

UNKNOWN

Biochemical Role of Matrix Metalloproteinase -9 in Rheumatoid Arthritis

NCT06494813

Rheumatoid Arthritis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PCSK9

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatoid arthritis

Patients with rheumatoid arthritis (n=25).

Enzyme-linked immunosorbent assay for PCSK9

Intervention Type DIAGNOSTIC_TEST

Enzyme-linked immunosorbent assay for plasma PCSK9

Rheumatoid arthritis complicated atrial fibrillation

Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).

Enzyme-linked immunosorbent assay for PCSK9

Intervention Type DIAGNOSTIC_TEST

Enzyme-linked immunosorbent assay for plasma PCSK9

healthy volunteers

Healthy volunteers (n=25).

Enzyme-linked immunosorbent assay for PCSK9

Intervention Type DIAGNOSTIC_TEST

Enzyme-linked immunosorbent assay for plasma PCSK9

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enzyme-linked immunosorbent assay for PCSK9

Enzyme-linked immunosorbent assay for plasma PCSK9

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Rheumatoid arthritis
2. Rheumatoid arthritis combined with AF

Exclusion Criteria

1\. (1) History of hypertension, diabetes, cardiovascular disease, severe impairment of liver function, severe renal insufficiency.

(2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.

2\. (1) History of hypertension, diabetes, cardiovascular disease (except for AF), severe impairment of liver function, severe renal insufficiency.

(2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes